Chapter 2 — Key Takeaways

How Peptides Work in Your Body

The core claims

A peptide does not do anything — it says something. It binds the outside of a cell and never enters. The cell performs the action, using its own machinery. Effect therefore depends on who is listening and what they are equipped to do.

Binding is induced fit, not lock and key. Both partners flex and adjust. Binding is reversible, an equilibrium rather than a switch. And binding is not the same as activating — an antagonist binds perfectly and produces nothing.

The cell detects the receptor's shape change, not the peptide. The message crosses the membrane as a conformational change. That is signal transduction.

Most peptide receptors are GPCRs — seven-transmembrane proteins, roughly 800 of them in humans, the target of about a third of all approved drugs. Cascade: peptide → receptor shape change → G protein → effector enzyme → second messenger (usually cAMP) → kinases → cellular response → termination.

Amplification is why trace amounts matter. One bound molecule produces thousands of downstream events. Circulating GLP-1 is picomolar and reorganizes pancreatic behavior. This is also why an unverified concentration is a serious problem, not a minor one.

Five ligand types: agonist (activates), antagonist (blocks), partial agonist (activates submaximally — and reduces signaling when a full agonist is present), inverse agonist (drops below baseline), biased agonist (activates some downstream arms and not others).

Affinity, potency, and efficacy are three different things. Affinity = how tightly it binds. Potency = how much you need (EC50). Efficacy = the ceiling. Marketing quotes whichever looks best, usually affinity, which is often the least clinically relevant.

Four termination mechanisms, and only two are engineerable. Degrade the peptide and clear it — both defeatable by chemical modification. Desensitize the receptor and downregulate it — not defeatable, because they are decisions the target cell makes. A longer-lasting agonist pushes harder on the machinery that shuts it down.

Expect tolerance when you override an intact system; expect durability when you replace an absent one. This single rule predicts a great deal, from GLP-1 weight regain to why insulin works for decades.

The rule to carry forward

Mechanism is necessary and never sufficient.

Seven steps separate "activates a receptor" from "benefit exceeds harm." Roughly nine in ten compounds entering human trials fail somewhere along them — every one backed by a mechanism somebody believed in.

Mechanism is strong evidence against and weak evidence for. It takes one broken step to stop a chain and all seven to complete one. Anyone using mechanism symmetrically is making an error, whichever side they land on.

Evidence ratings issued in this chapter

This is a mechanistic ✅ and it licenses nothing clinical. Whether any GLP-1 agonist helps any patient is a separate claim with separate evidence, rated separately in Chapter 8. Watch for sources that earn the first and report the second.

The seven-step gap (memorize this)

  ① binds and activates the receptor          ← cell assay
  ② reaches the target tissue in a person     ← absorption, distribution, barriers
  ③ at a concentration that matters, long enough
  ④ downstream machinery intact and available
  ⑤ the system does not fully compensate      ← homeostasis, tolerance
  ⑥ an outcome a person notices improves      ← REQUIRES A TRIAL
  ⑦ benefit exceeds harm                      ← REQUIRES A TRIAL

Key terms

ligand · receptor · induced fit · agonist · antagonist · partial agonist · inverse agonist · biased agonism · GPCR · G protein · second messenger · cAMP · signal transduction · amplification · affinity · potency · efficacy · EC50 · dose-response curve · desensitization · receptor downregulation · tolerance · tachyphylaxis · autocrine · paracrine · endocrine · neuromodulator

What you can now evaluate

• ✅ what "activates the [X] receptor" does and does not establish
• ✅ whether a claim is quoting affinity, potency, or efficacy — and which one it should be quoting
• ✅ why selectivity degrades at high concentration, and why "it's selective" is not a safety argument
• ✅ when to expect a therapy to develop tolerance, and when not to
• ✅ why "it stopped working so I took more" is a specifically bad instinct
• ✅ where a mechanism claim sits on the seven-step chain
• ❌ not yet: how to read the trial that would settle steps 6 and 7. That is Chapter 5.

The one-sentence version

A peptide is a message, the cell is the actor, and knowing that the message was delivered tells you almost nothing about what the cell decided to do with it.

Next: Chapter 3 — the whole system the message arrives in: hypothalamic-pituitary axes, feedback loops, and why supplementing a hormone suppresses your own.